Blog
RSS FeedPosted by Michael Wonder on 22 Feb 2017
FDA’s Pazdur and Blumenthal: the march of checkpoint inhibitors will continue
21 February 2017 - More approvals of new immune-checkpoint inhibitors, targeted and personalised therapies, as well as the use of ...
Posted by Michael Wonder on 14 Feb 2017
FDA drug trials snapshots and diversity when testing new drugs
13 February 2017 - Did you know that some drugs affect men and women differently? ...
Posted by Michael Wonder on 13 Feb 2017
The challenges of generating evidence to support precision medicine
13 February 2017 - Major recent advances in science and technology now enable new kinds of measurements that can characterise an ...
Posted by Michael Wonder on 03 Feb 2017
U.S. House panel to take up bill to spur generic drug development
2 February 2017 - A U.S. House of Representatives subcommittee will take up bipartisan legislation next week to foster generic ...
Posted by Michael Wonder on 02 Feb 2017
Drug development challenges for small biopharmaceutical companies
1 February 2017 - Small biopharmaceutical companies are becoming increasingly important as drivers of innovation in drug development. ...
Posted by Michael Wonder on 31 Jan 2017
Trump pushes drug makers for lower prices, more U.S. production
31 January 2017 - U.S. President Donald Trump on Tuesday met with top executives from some of the biggest drug ...
Posted by Michael Wonder on 21 Jan 2017
Benefit-risk assessments at the US Food and Drug Administration: finding the balance
20 January 2017 - The US FDA’s independent evaluation of medical products for safety and effectiveness prior to granting approval ...
Posted by Michael Wonder on 19 Jan 2017
Statement from FDA Commissioner announcing FDA Oncology Center of Excellence launch
19 January 2017 - Today the U.S. FDA is establishing the Oncology Center of Excellence (OCE) and appointing Dr. Richard ...
Posted by Michael Wonder on 17 Jan 2017
Composite endpoints and the distortion of risk–benefit analysis
17 January 2017 - Evidence-based medicine is a reassuring phrase, but when we prescribe has the evidence for safety and efficacy ...
Posted by Michael Wonder on 17 Jan 2017
Drug makers manipulate orphan drug rules to create prized monopolies
17 January 2017 - More than 30 years ago, Congress overwhelmingly passed a landmark health bill aimed at motivating pharmaceutical ...
Posted by Michael Wonder on 13 Jan 2017
Interpretation of surrogate endpoints in the era of the 21st Century Cures Act
14 January 2017 - Surrogate endpoints are commonly used in clinical trials to get quicker results, but Kevin Knopf and ...
Posted by Michael Wonder on 12 Jan 2017
What Trump gets wrong about drug companies
12 January 2017 - President-elect Donald Trump was hardly timid in declaring Wednesday that drug companies are “getting away with ...
Posted by Michael Wonder on 12 Jan 2017
Biopharma needs to stop getting blindsided by Donald Trump
11 January 2017 - The day after Donald Trump won the US presidential election, pharma and biotech investors seemed to ...
Posted by Michael Wonder on 11 Jan 2017
National Cancer Institute and drug companies aim to speed up clinical trials
11 January 2017 - The National Cancer Institute launched an effort Wednesday to speed up clinical trials by getting researchers ...
Posted by Michael Wonder on 08 Jan 2017
Don’t thank big government for medical breakthroughs
5 January 2017 - New cures come from private research, not cash dumped into the National Institutes of Health. ...